Chemoprophylaxis To Prevent HIV Infection: An Interim Guidance for Clinicians
The New England Journal of Medicine published the results of an historic HIV prevention study on November 23, 2010: Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men by Grant et al. The study demonstrated that men who were assigned to take a combination antiretroviral medication orally on a daily basis decreased their HIV risk by almost half compared to those assigned to take a placebo.
As this is the first published study on this novel approach to HIV prevention, called PrEP (pre-exposure prophylaxis), using available oral medication it is likely that clinicians will be approached by patients requesting PrEP for HIV prevention. The Fenway Institute offers this information for clinicians to review the findings of the study and as interim guidance for prescribing and supporting patients seeking PrEP in advance of development of guidelines by any government agencies or professional societies.
Click here to check it out.
[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]